Vishal Rana, MD
Hematology & Oncology · Colorado Springs, CONPI 1831307438
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,169 of the $33,695 with a category attached, or 77.7%. 14 manufacturers reported payments, led by Seagen Inc. at 32.9% of the total. Reporting peaked in 2021 at $14,060 and has fallen 87.6% since, to $1,740 in 2025.
Across 43 payments — averaging $783.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$11K
- AstraZeneca$7K
- Gilead$6K
- ADC Therapeutics America, Inc.$2K
- Bayer$2K
- Beigene USA, Inc.$1K
- plus $5K from 8 others
Across 78 payments — averaging $4218.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$161K
- Acerta Pharma LLC$118K
- Incyte Corporation$49K
- Merck$660
What the payments were for
- Consulting fees$26,16978%
- Speaking & faculty fees$3,55011%
- Travel & lodging$3,21510%
- Food & beverage$7352%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 10 | $11,074 |
| AstraZeneca | 9 | $6,804 |
| Gilead | 10 | $5,727 |
| ADC Therapeutics America, Inc. | 1 | $2,000 |
| Bayer | 1 | $1,713 |
| Beigene USA, Inc. | 1 | $1,350 |
| Rigel Pharmaceuticals, Inc. | 2 | $1,315 |
| Daiichi Sankyo Inc. | 2 | $1,175 |
| Johnson & Johnson | 2 | $1,090 |
| GSK | 1 | $975 |
| Cepheid | 1 | $350 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $95 |
| Amgen | 1 | $16 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,695 in reported general payments places this provider in the 80th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 12 | $208 |
| Prochlorperazine Maleate | 12 | $204 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Colorado Springs
- Geetika SrivastavaColorado Springs$17K
- Matthew LogsdonColorado Springs$11K
- Dax KurbegovColorado Springs$10K
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Manojkumar BupathiLittleton$312K
- Steven SchusterFort Collins$298K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.